Tobias Walbert1, Vinay K Puduvalli1, Martin J B Taphoorn1, Andrew R Taylor1, Rakesh Jalali1. 1. Departments of Neurosurgery and Neurology, Henry Ford Health System, Detroit, Michigan (T.W., A.R.T.); The Ohio State University Comprehensive Cancer Center, Columbus, Ohio (V.K.P.); VU University Medical Center, Amsterdam, Netherlands (M.J.B.T.); Medical Center Haaglanden, The Hague, Netherlands (M.J.B.T.); Tata Memorial Centre, Mumbai, India (R.J.).
Abstract
BACKGROUND: Brain tumor patients have limited survival and suffer from high morbidity requiring specific symptom management. Specialized palliative care (PC) services have been developed to address these symptoms and provide end-of-life treatment. Global utilization patterns of PC in neuro-oncology are unknown. METHODS: In a collaborative effort between the Society for Neuro-Oncology (SNO), the European Association of Neuro-Oncology (EANO), and the Asian Society for Neuro-Oncology (ASNO), a 22-question survey was distributed. Wilcoxon 2-sample and Kruskal-Wallis tests were used to assess differences in responses. RESULTS: Five hundred fifty-two evaluable responses were received. The most significant differences were found between Asia-Oceania (AO) and Europe as well as AO and United States/Canada (USA-C). USA-C providers had more subspecialty training in neuro-oncology, but most providers had received no or minimal training in palliative care independent of region. Providers in all 3 regions reported referring patients at the onset of symptoms requiring palliation, but USA-C and European responders refer a larger total proportion of patients to PC (P < .001). Physicians in AO and Europe (both 46%) as well as 29% of USA-C providers did not feel comfortable dealing with end-of-life issues. Most USA-C patients (63%) are referred to hospice compared with only 8% and 19% in AO and Europe (P < .001), respectively. CONCLUSION: This is the first report describing global differences of PC utilization in neuro-oncology. Significant differences in provider training, culture, access, and utilization were mainly found between AO and USA-C or AO and Europe. PC patterns are more similar in Europe and USA-C.
BACKGROUND: Brain tumor patients have limited survival and suffer from high morbidity requiring specific symptom management. Specialized palliative care (PC) services have been developed to address these symptoms and provide end-of-life treatment. Global utilization patterns of PC in neuro-oncology are unknown. METHODS: In a collaborative effort between the Society for Neuro-Oncology (SNO), the European Association of Neuro-Oncology (EANO), and the Asian Society for Neuro-Oncology (ASNO), a 22-question survey was distributed. Wilcoxon 2-sample and Kruskal-Wallis tests were used to assess differences in responses. RESULTS: Five hundred fifty-two evaluable responses were received. The most significant differences were found between Asia-Oceania (AO) and Europe as well as AO and United States/Canada (USA-C). USA-C providers had more subspecialty training in neuro-oncology, but most providers had received no or minimal training in palliative care independent of region. Providers in all 3 regions reported referring patients at the onset of symptoms requiring palliation, but USA-C and European responders refer a larger total proportion of patients to PC (P < .001). Physicians in AO and Europe (both 46%) as well as 29% of USA-C providers did not feel comfortable dealing with end-of-life issues. Most USA-C patients (63%) are referred to hospice compared with only 8% and 19% in AO and Europe (P < .001), respectively. CONCLUSION: This is the first report describing global differences of PC utilization in neuro-oncology. Significant differences in provider training, culture, access, and utilization were mainly found between AO and USA-C or AO and Europe. PC patterns are more similar in Europe and USA-C.
Entities:
Keywords:
end-of-life; glioblastoma; glioma; hospice; palliative care
Authors: Saskia C C M Teunissen; Wendy Wesker; Cas Kruitwagen; Hanneke C J M de Haes; Emile E Voest; Alexander de Graeff Journal: J Pain Symptom Manage Date: 2007-05-23 Impact factor: 3.612
Authors: Carlos Centeno; David Clark; Thomas Lynch; Javier Racafort; David Praill; Liliana De Lima; Anthony Greenwood; Luis Alberto Flores; Simon Brasch; Amelia Giordano Journal: Palliat Med Date: 2007-09 Impact factor: 4.762
Authors: Martin J van den Bent; Antoine F Carpentier; Alba A Brandes; Marc Sanson; Martin J B Taphoorn; Hans J J A Bernsen; Marc Frenay; Cees C Tijssen; Wolfgang Grisold; Laslo Sipos; Hanny Haaxma-Reiche; Johannes M Kros; Mathilde C M van Kouwenhoven; Charles J Vecht; Anouk Allgeier; Denis Lacombe; Thierry Gorlia Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: Lauren E Abrey; David N Louis; Nina Paleologos; Andrew B Lassman; Jeffrey J Raizer; Warren Mason; Jonathan Finlay; David R MacDonald; Lisa M DeAngelis; J Gregory Cairncross Journal: Neuro Oncol Date: 2007-04-13 Impact factor: 12.300
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Michael D Prados; Wendy Seiferheld; Howard M Sandler; Jan C Buckner; Theodore Phillips; Christopher Schultz; Raul Urtasun; Richard Davis; Philip Gutin; Terrence L Cascino; Harry S Greenberg; Walter J Curran Journal: Int J Radiat Oncol Biol Phys Date: 2004-03-15 Impact factor: 7.038
Authors: Roy E Strowd; Erin M Dunbar; Hui K Gan; Sylvia Kurz; Justin T Jordan; Jacob J Mandel; Nimish A Mohile; Kathryn S Nevel; Jennie W Taylor; Nicole J Ullrich; Mary R Welch; Andrea Wasilewski; Maciej M Mrugala Journal: Neurooncol Pract Date: 2022-01-17
Authors: Marissa Barbaro; Craig D Blinderman; Fabio M Iwamoto; Teri N Kreisl; Mary R Welch; Yazmin Odia; Laura E Donovan; Adela E Joanta-Gomez; Katharine A Evans; Andrew B Lassman Journal: Neurology Date: 2021-11-18 Impact factor: 9.910
Authors: Rita C Crooms; Hung-Mo Lin; Sean Neifert; Stacie G Deiner; Jess W Brallier; Nathan E Goldstein; Jonathan S Gal; Laura P Gelfman Journal: J Palliat Med Date: 2021-06-24 Impact factor: 2.947